Alzheimer's gene test fails ethics panel criteria
This article was originally published in Clinica
A Stanford University ethics panel has said a genetic blood test for determining susceptibility to Alzheimer's disease should not be used because it is not accurate enough.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.